TY - JOUR
T1 - The Modifying Effect of a Functional Variant at the miRNA Binding Site in E2F1 Gene on Recurrence of Oropharyngeal Cancer Patients with Definitive Radiotherapy
AU - Zhang, Hua
AU - Sturgis, Erich
AU - Zhu, Lijun
AU - Lu, Zhongming
AU - Tao, Ye
AU - Zheng, Hongliang
AU - Li, Guojun
N1 - Funding Information:
The authors thank Margaret Lung, Kathryn L. Tipton, Liliana Mugartegui, and Angeli Fairly for their help with participant recruitment and Li-E Wang for laboratory management. This work was supported by start-up funds from The University of Texas MD Anderson Cancer Center (to E.M.S.), a National Institutes of Health Head and Neck Specialized Program of Research Excellence Career Development Award (P50CA097007 to E.M.S.), an Institutional Research Grant from The University of Texas MD Anderson Cancer Center (to E.M.S.), and other National Institutes of Health grants: grants ES011740 and CA131274 (to Q.W.), a Clinician Investigator Award (K12CA88084 to E.M.S.), a Cancer Center Support Grant to The University of Texas MD Anderson Cancer Center (CA16672), and grants CA135679, CA133099, and 1R03CA186261-01A1 (to G.L.).
Publisher Copyright:
© 2018
PY - 2018/6
Y1 - 2018/6
N2 - Human papillomavirus (HPV) activates E2F1-driven transcription via the E7-RB-E2F1 pathway. A polymorphism in the 3’ UTR of E2F1 gene may disrupt a binding site for miRNA and may affect its transcription level, thus modifying the susceptibility to radiotherapy and outcomes through this pathway. We evaluated the association of a polymorphism at the 3'UTR miRNA binding site of E2F1 gene (rs3213180) with risk of recurrence of SCCOP in a cohort of 1008 patients. Log-rank test and univariate and multivariable Cox models were used to evaluate the associations. Compared with patients with E2F1-rs3213180 GG homozygous genotype, the patients with E2F1-rs3213180GC + CC variant genotypes had significantly better disease-free survival (log-rank P <.001) and decreased risk of SCCOP recurrence (HR, 0.4, 95% CI, 0.3–0.5) after multivariable adjustment. Furthermore, among patients with HPV16-positive tumors, the patients with E2F1-rs3213180 GC + CC variant genotypes had significantly better disease-free survival rates (log-rank P <.001) and lower recurrence risk than those with E2F1-rs3213180 GG homozygous genotype (HR, 0.2, 95% CI, 0.1–0.4). Our findings suggest that E2F1-rs3213180 polymorphism may modulate the risk of recurrence in SCCOP patients, particularly for patients with HPV16-positive tumors of SCCOP. However, future larger population and functional studies are warranted to validate these results.
AB - Human papillomavirus (HPV) activates E2F1-driven transcription via the E7-RB-E2F1 pathway. A polymorphism in the 3’ UTR of E2F1 gene may disrupt a binding site for miRNA and may affect its transcription level, thus modifying the susceptibility to radiotherapy and outcomes through this pathway. We evaluated the association of a polymorphism at the 3'UTR miRNA binding site of E2F1 gene (rs3213180) with risk of recurrence of SCCOP in a cohort of 1008 patients. Log-rank test and univariate and multivariable Cox models were used to evaluate the associations. Compared with patients with E2F1-rs3213180 GG homozygous genotype, the patients with E2F1-rs3213180GC + CC variant genotypes had significantly better disease-free survival (log-rank P <.001) and decreased risk of SCCOP recurrence (HR, 0.4, 95% CI, 0.3–0.5) after multivariable adjustment. Furthermore, among patients with HPV16-positive tumors, the patients with E2F1-rs3213180 GC + CC variant genotypes had significantly better disease-free survival rates (log-rank P <.001) and lower recurrence risk than those with E2F1-rs3213180 GG homozygous genotype (HR, 0.2, 95% CI, 0.1–0.4). Our findings suggest that E2F1-rs3213180 polymorphism may modulate the risk of recurrence in SCCOP patients, particularly for patients with HPV16-positive tumors of SCCOP. However, future larger population and functional studies are warranted to validate these results.
UR - http://www.scopus.com/inward/record.url?scp=85044141568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044141568&partnerID=8YFLogxK
U2 - 10.1016/j.tranon.2018.02.022
DO - 10.1016/j.tranon.2018.02.022
M3 - Article
C2 - 29574328
AN - SCOPUS:85044141568
SN - 1936-5233
VL - 11
SP - 633
EP - 638
JO - Translational Oncology
JF - Translational Oncology
IS - 3
ER -